Category: Investment, Biotech, Biodefense
Biotech Stock News; Aethlon Medical (OTCBB: AEMD) Announces the Appointment of Dr. Stephen Z. Fadem to its Extracorporeal Science Advisory Board
Visit this company: www.aethlonmedical.com
SAN DIEGO - September 26, 2012 (Investorideas.com newswire) - Aethlon Medical, Inc. (OTCBB: AEMD), announced today that Dr. Stephen Z. Fadem has agreed to join the company's Extracorporeal Science Advisory Board. Dr. Fadem is active as a practicing Houston nephrologist, teacher, lecturer and researcher. He began practice in 1978 after completing a renal fellowship at The University of Texas Health Science Center in San Antonio. He is a graduate of the University of Oklahoma College of Medicine, and did his internal medicine residency at The University of Texas and MD Anderson Hospital in Houston. He is a Clinical Professor of Medicine, Baylor College of Medicine.
Dr. Fadem is also a Fellow of the American College of Physicians, Fellow of the American Society of Nephrology and diplomate of the American Board of Quality Assurance and Utilization Review Physicians. He has served as the Chairman of the (National Kidney Foundation (NKF) of Southeast Texas Medical Advisory Board, and has received their Lifetime Achievement Award and the Myron L. Jenkins Award.
On a national level, Dr. Fadem is co-chairman of the Medical Advisory Board of the American Association of Kidney Patients (AAKP), and a past vice-president of the AAKP Board of Directors. He has also served on the Board of Directors of the Renal Physicians Association, and actively serves on two national RPA committees, the Government Affairs Committee and the Health Finance Committee. Dr. Fadem has been active in the Forum of ESRD Networks, was a member of the CMS Clinical Performance Measures Committee. He serves as a consultant to the computer industry in the development of CKD management software and is the founder of Touchcalc, a software design company. He lectures frequently on dialysis management, preventive nephrology, vascular calcification, anemia, patient education, CKD education, and computer technology and computer security. Dr. Fadem is the co-editor of AAKP Renalife, and is a reviewer for several peer-reviewed journals.
Dr. Fadem has been nationally recognized, receiving the AAKP Nova Award, the NKF Distinguished Service Award. He has also received the NKF Presidents Award. He has been awarded the Peter Lundin Award for his contributions to patient education and The Visionary Award for his contributions to CKD education. He has also been named as one of America's Top Doctors by Castle Connolly and US News and World Report.
About Aethlon Medical
The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the ability for the Company to derive business partnerships or future revenue streams using the Aethlon ADAPT™ system including the ability to introduce a targeted breast cancer therapy known as HER2osome™, there is no assurance that FDA will approve the initiation of the company's clinical programs or provide market clearance of the company's products, the ability to achieve the goals set out in the DARPA contract, future human studies of the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer therapies, the company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
James A. Joyce
Chairman and CEO
Chief Financial Officer
Visit the AETHLON MEDICAL INC (OTC BB: AEMD) showcase profile page on Investorideas.comDisclosure/Disclaimer: AETHLON MEDICAL INC (OTC BB: AEMD) Investorideas.com is paid by AEMD to publish news and distribute content through Investordeas.com Newswire and its syndicated partners and blogs
This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com